Localized scleroderma, or morphea, is a chronic inflammatory disease that involves skin and subcutaneous tissues, causing skin sclerosis. Several classifications have been published including those of Laxer and Zulian1: circumscribed, linear, generalized, pansclerotic, or mixed. In contrast to systemic sclerosis, morphea does not involve internal organs. Generalized morphea (GM) is a form of severe morphea with substantial effect on quality of life and survival. First-line systemic treatments for severe morphea include phototherapy, systemic steroids, and methotrexate. Data regarding therapeutic management of GM are scarce, limited to case reports and small case series. We describe a case of GM that was successfully treated with everolimus, an mTOR (mechanistic target of rapamycin) inhibitor.
Frumholtz L, Roux J, Bagot M, Rybojad M, Bouaziz J. Treatment of Generalized Deep Morphea With Everolimus. JAMA Dermatol. 2016;152(10):1170-1172. doi:10.1001/jamadermatol.2016.2338